You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 2, 2025

Details for Patent: RE39706


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: RE39706
Title:Crystalline form of a vitamin D analogue
Abstract:The present invention relates to calcipotriol hydrate--a new crystalline form of calcipotriol--with superior technical properties and with superior stability.
Inventor(s): Hansen; Erik Torngaard (Hundested, DK), Andersen; Niels Smidt Rastrup (Vanlose, DK), Ringborg; Lene Hoffmeyer (Bronshoj, DK)
Assignee: Leo Pharma A/S (Ballerup, DK)
Application Number:10/986,575
Patent Claim Types:
see list of patent claims
Compound; Composition; Use; Formulation;
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent RE39706: A Detailed Analysis

Introduction

When analyzing a patent, particularly a reissued patent like the United States Patent RE39706, it is crucial to delve into the scope and claims to understand its validity, applicability, and impact on the patent landscape. This article will provide a comprehensive analysis of these aspects, drawing from relevant legal and technical perspectives.

What is a Reissued Patent?

A reissued patent is a new patent that is issued to replace an original patent, often to correct errors or to broaden or narrow the claims of the original patent. This process is governed by 35 U.S.C. § 251, which requires that the reissue claims must be directed to the same invention as the original patent[2].

Determining the Scope of the Patent

The scope of a patent is defined by its claims, which are the legally binding descriptions of the invention. To determine the scope, one must analyze the language and limitations of these claims.

Claim Language and Metrics

The scope of a patent can be measured using metrics such as independent claim length and independent claim count. These metrics are indicative of the breadth and clarity of the patent claims. Broader claims, often characterized by longer lengths and higher counts, can be more contentious and may lead to increased licensing and litigation costs[3].

Original Patent Requirements

For a reissued patent, the claims must align with the invention disclosed in the original patent. The Supreme Court has emphasized that reissue claims must fully describe and claim the very invention intended to be secured in the original patent. Any omission or addition of essential steps or features can render the reissue claims invalid[2].

Analyzing the Claims of RE39706

To analyze the claims of RE39706, one must compare them against the original patent to ensure they meet the requirements of 35 U.S.C. § 251.

Comparison with Original Patent

The reissue claims must mirror the invention disclosed in the original patent specification. If the reissue claims broaden or narrow the scope in a way that introduces new or omits essential features, they may not meet the original patent requirement. For instance, if the original patent specified a particular component as necessary, omitting this component in the reissue claims could invalidate them[2].

Essential Features and Limitations

Each claim in the reissued patent must include every feature of the subject matter claimed in the original patent. If any feature is omitted or altered significantly, it could be considered a different invention, thus violating the reissue requirements. The court has consistently held that reissue claims broadening a limitation to cover undisclosed alternatives to a particular feature do not meet the original patent requirement[2].

Inventorship and Contributions

Inventorship is another critical aspect of patent law. It is defined by the conception of the invention, not merely the reduction to practice.

Conception vs. Reduction to Practice

An inventor is someone who conceives the subject matter of at least one claim of the patent. Conception is complete when an idea is sufficiently definite and permanent to permit one with ordinary skill in the field to reduce it to practice without undue experimentation. Contributions that merely involve reducing an invention to practice or performing experiments do not qualify someone as an inventor[1].

Joint Inventorship

Joint inventorship occurs when two or more persons collaborate to produce the invention through aggregate efforts. However, mere explanation of well-known principles or current state of the art does not qualify someone as a joint inventor. The collaboration must be significant and contribute to the conception of the invention[1].

Patent Landscape and Implications

The patent landscape is influenced by the scope and validity of patents like RE39706.

Impact on Innovation

Broad or overly broad patents can diminish incentives for innovation by increasing licensing and litigation costs. Narrower claims, on the other hand, are associated with a higher probability of grant and a shorter examination process, which can foster innovation by providing clearer boundaries and reducing legal disputes[3].

Litigation and Enforcement

Errors in inventorship or deceptive intent in naming inventors can render a patent invalid and unenforceable. Even if the correct inventorship can be established later, a patent obtained through fraud remains unenforceable. This highlights the importance of accurate and honest disclosure during the patent application process[1].

Case Studies and Precedents

Several court cases provide valuable insights into the analysis of reissued patents.

In Re FLOAT'N'GRILL LLC

In this case, the Court of Appeals for the Federal Circuit affirmed that reissue claims must cover the invention disclosed in the original patent. The court held that broadening claims to cover undisclosed alternatives to a particular feature does not meet the original patent requirement[2].

Antares and Other Cases

In other cases, such as Antares, the court has consistently applied the principle that reissue claims must align with the original patent's disclosure. Any attempt to broaden claims to cover new aspects not originally disclosed can result in the invalidation of the reissue claims[2].

Key Takeaways

  • Scope and Claims Alignment: Reissue claims must align with the invention disclosed in the original patent to be valid.
  • Essential Features: Each claim must include every feature of the subject matter claimed in the original patent.
  • Inventorship: Inventorship is determined by the conception of the invention, not the reduction to practice.
  • Patent Landscape: The scope and validity of patents influence innovation and litigation costs.
  • Legal Compliance: Accurate and honest disclosure is crucial during the patent application process to avoid invalidation.

FAQs

Q: What is the primary requirement for reissue claims under 35 U.S.C. § 251?

A: The primary requirement is that the reissue claims must be directed to the same invention as the original patent.

Q: How is the scope of a patent measured?

A: The scope can be measured using metrics such as independent claim length and independent claim count.

Q: What constitutes an inventor in patent law?

A: An inventor is someone who conceives the subject matter of at least one claim of the patent.

Q: Can reissue claims broaden the scope of the original patent?

A: No, reissue claims cannot broaden the scope to cover undisclosed alternatives to a particular feature without violating the original patent requirement.

Q: What are the consequences of deceptive intent in naming inventors?

A: A patent obtained through deceptive intent remains unenforceable even if the correct inventorship can be established later.

Sources

  1. Determining Inventorship for US Patent Applications - Oregon State University
  2. In Re FLOAT'N'GRILL LLC - Court of Appeals for the Federal Circuit
  3. Patent Claims and Patent Scope - SSRN
  4. United States Reissued Patent - googleapis.com
  5. Tracking system for locational tracking of ... - Unified Patents

More… ↓

⤷  Subscribe


Drugs Protected by US Patent RE39706

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: RE39706

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9300763Jan 15, 1993
PCT Information
PCT FiledJanuary 15, 1993PCT Application Number:PCT/DK94/00011
PCT Publication Date:July 21, 1994PCT Publication Number: WO94/15912

International Family Members for US Patent RE39706

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 159717 ⤷  Subscribe
Australia 5857394 ⤷  Subscribe
Australia 663249 ⤷  Subscribe
Canada 2151730 ⤷  Subscribe
China 1040746 ⤷  Subscribe
China 1115979 ⤷  Subscribe
Germany 69406529 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.